Yazar "Canpolat, Nur" seçeneğine göre listele
Listeleniyor 1 - 7 / 7
Sayfa Başına Sonuç
Sıralama seçenekleri
Öğe Cardiometabolic risk factors in pediatric kidney transplant recipients(AVES, 2023) Saygılı, Seha Kamil; Karabağ Yılmaz, Esra; Kezer, Seçil; Dedeoğlu, Reyhan; Kaplan Kılıç, Şevval; Çiçek, Rümeysa Yasemin; Gülmez, Rüveyda; Demirgan, Ebru Burcu; Ağbaş, Ayşe; Eliçevik, Mehmet; Çalışkan, Salim; Canpolat, NurObjective: There is an increased risk of obesity and metabolic syndrome among kidney transplant recipients, which adversely affects cardiovascular and renal outcomes in these patients. The present study aims to investigate the prevalence of metabolic syndrome in pediatric kidney transplant recipients and the associations of metabolic syndrome with cardiovascular disease and graft function. Materials and Methods: This cross-sectional, single-center study included 52 kidney transplant recipients (27 males) transplanted before 18 years of age. All subjects underwent a comprehensive assessment that included anthropometric and blood pressure measurements and laboratory tests. Metabolic syndrome was defined based on the recent recommendations of the Pediatric Renal Nutrition Taskforce. Left ventricular hypertrophy was assessed as a risk factor for cardiovascular disease, and estimated glomerular filtration rate was assessed to determine graft function. Results: The median age of patients was 15.9 (13.8;18.4) years, and the median follow-up time was 35.5 (20.0;62;0) months after transplantation. Nineteen patients (36.5%) were obese or overweight, 43 (83%) had hypertension or controlled hypertension, 23 (44%) had dyslipidemia, and 9 (17%) had hyperglycemia. Ten patients (19.2%) were diagnosed with metabolic syndrome. Twenty-eight patients (54%) had left ventricular hypertrophy. The prevalence of left ventricular hypertrophy was higher in patients with metabolic syndrome than in those without metabolic syndrome (90% vs. 45%, P =.014), whereas estimated glomerular filtration rate did not differ between the 2 groups. Conclusion: Cardiometabolic risk factors are common in pediatric kidney transplant recipients. Approximately one-fifth of patients have metabolic syndrome, and left ventricular hypertrophy is much more common among patients with metabolic syndrome. However, there is no relationship between metabolic syndrome and graft dysfunction.Öğe COVID-19 in children with chronic dialysis and kidney transplantation: A multicenter study from Istanbul(Springer, 2021) Canpolat, Nur; Yürük Yıldırım, Zeynep; Yıldız, Nurdan; Taşdemir, Mehmet; Göknar, Nilüfer; Evrengül, Havva; Gülmez, Rüveyda; Aksu, Bağdagül; Dursun, Hasan; Özçelik, Gül; Yavaşcan, Önder; Çiçek, Rümeysa Yasemin; Tülpar, Sebahat; Övünç Hacıhamdioğlu, Duygu; Nayır, Ahmet; Alpay, Harika[Abstract Not Available]Öğe COVID-19 in pediatric nephrology centers in Turkey(Springer, 2021) Bakkaloğlu, Sevcan Azime; Özdemir Atikel, Yeşim; Leventoğlu, Emre; Nalcacıoğlu, Hülya; Dursun, İsmail; Poyrazoğlu, Hakan; Dursun, Hasan; Yürük Yıldırım, Zeynep; Yıldız, Nurdan; Kaya Aksoy, Gülşah; Akman, Sema; Taşdemir, Mehmet; Bilge, Ilmay; Çelakıl, Mehtap; Demircioğlu Kılıç, Beltinge; Zırhlı Selçuk, Şenay; Canpolat, Nur; Kargın Çakıcı, Evrim; Özlü, Sare Gülfem; Tülpar, Sebahat; Yüksel, Selçuk; Atmış, Bahriye; Sürmeli Döven, Serra; Taner, Sevgin; Ertan, Pelin; Kavaz, Aslı; Torun Bayram, Meral; Kalyoncu, Mukaddes; Gülleroğlu, Kaan; Kabasakal, Caner; Kasap Demir, Belde; Çiçek, Rümeysa Yasemin; Dönmez, Osman; Kara, Aslıhan; Yavaşcan, Önder; Özçelik, Gül; Gezgin Yıldırım, Deniz; Güler, Muhammet Akif; Sönmez, Ferah; Topaloğlu, Rezan; Alpay, Harika[Abstract Not Available]Öğe COVID-19 in pediatric nephrology centers in Turkey(Turkiye Klinikleri, 2022) Leventoğlu, Emre; Özdemir Atikel, Yeşim; Nalçacıoğlu, Hülya; Dursun, İsmail; Dursun, Hasan; Yürük Yıldırım, Zeynep; Yıldız, Nurdan; Kaya Aksoy, Gülşah; Taşdemir, Mehmet; Çelakil, Mehtap; Demircioğlu Kılıç, Beltinge; Zırhlı Selçuk, Şena; Canpolat, Nur; Kargın Çakıcı, Evrim; Özlü, Sare Gülfem; Tülpar, Sebahat; Yüksel, Selçuk; Atmış, Bahriye; Sürmeli Döven, Serra; Taner, Sevgin; Ertan, Pelin; Kavaz, Aslı; Torun Bayram, Meral; Kalyoncu, Mukaddes; Gülleroğlu, Kaan; Kabasakal, Caner; Kasap Demir, Belde; Çiçek, Rümeysa Yasemin; Bilge, İlmay; Dönmez, Osman; Kara, Aslıhan; Yavaşcan, Önder; Özçelik, Gül; Gezgin Yıldırım, Deniz; Güler, Muhammet Akif; Sönmez, Ferah; Poyrazoğlu, Hakan; Akman, Sema; Topaloğlu, Rezan; Alpay, Harika; Bakkaloğlu, Sevcan AzimeBackground/aim: There is limited data on COVID-19 disease in children with kidney disease. We aimed to investigate the characteristics and prognosis of COVID-19 in pediatric nephrology patients in Turkey. Materials and methods: This was a national, multicenter, retrospective cohort study based on an online survey evaluating the data between 11th March 2020 and 11th March 2021 as an initial step of a detailed pediatric nephrology COVID-19 registry. Results: Two hundred and three patients (89 girls and 114 boys) were diagnosed with COVID-19. One-third of these patients (36.9%) were between 10–15 years old. Half of the patients were on kidney replacement therapy: kidney transplant (KTx) recipients (n = 56, 27.5%), patients receiving chronic hemodialysis (n = 33, 16.3%) and those on peritoneal dialysis (PD) (n = 18, 8.9%). Fifty-four (26.6%) children were asymptomatic. Eighty-two (40.3%) patients were hospitalized and 23 (28%) needed intensive care unit admission. Fifty-five percent of the patients were not treated, while the remaining was given favipiravir (20.7%), steroid (16.3%), and hydroxychloroquine (11.3%). Acute kidney injury developed in 19.5% of hospitalized patients. Five (2.4%) had MIS-C. Eighty-three percent of the patients were discharged without any apparent sequelae, while 7 (3.4%) died. One hundred and eight health care staff were infected during the study period. Conclusion: COVID-19 was most commonly seen in patients who underwent KTx and received HD. The combined immunosuppressive therapy and frequent exposure to the hospital setting may increase these patients’ susceptibility. Staff infections before vaccination era were alarming, various precautions should be taken for infection control, particularly optimal vaccination coverage.Öğe COVID-19 in pediatric patients undergoing chronic dialysis and kidney transplantation(Springer, 2022) Canpolat, Nur; Yürük Yıldırım, Zeynep; Yıldız, Nurdan; Taşdemir, Mehmet; Göknar, Nilüfer; Evrengül, Havva; Gülmez, Rüveyda; Aksu, Bağdagül; Dursun, Hasan; Özçelik, Gül; Yavaşcan, Önder; Çiçek, Rümeysa YaseminThe study aims to present the incidence of COVID-19 in pediatric patients undergoing renal replacement therapy (RRT) and to compare the severity and outcomes of the disease between the dialysis and kidney transplant (KTx) groups. This multicenter observational study was conducted between 1 April and 31 December 2020 in Istanbul. Members of the Istanbul branch of the Turkish Pediatric Nephrology Association were asked to report all confirmed cases of COVID-19 who were on RRT, as well as the number of prevalent RRT patients under the age of 20. A total of 46 confirmed cases of COVID-19 were reported from 12 centers, of which 17 were dialysis patients, and 29 were KTx recipients. Thus, the incidence rate of COVID-19 was 9.3% among dialysis patients and 9.2% among KTx recipients over a 9-month period in Istanbul. Twelve KTx recipients and three dialysis patients were asymptomatic (p = 0.12). Most of the symptomatic patients in both the dialysis and KTx groups had a mild respiratory illness. Only two patients, one in each group, experienced a severe disease course, and only one hemodialysis patient had a critical illness that required mechanical ventilation. In the entire cohort, one hemodialysis patient with multiple comorbidities died. Conclusion: While most cases are asymptomatic or have a mild disease course, pediatric patients undergoing dialysis and a kidney transplant are at increased risk for COVID-19. What is Known: In adult population, both dialysis patients and kidney transplant recipients are at increased risk for severe illness of COVID-19 and have higher mortality rate. Children with kidney transplantation are not at increased risk for COVID-19 and most have mild disease course. Data on children on dialysis are scarce. What is New: Pediatric patients undergoing dialysis and kidney transplantation have an increased risk for COVID-19. Most patients undergoing renal replacement therapy either on dialysis or transplanted develop asymptomatic or mild COVID-19 disease with a favorable outcome.Öğe Rituximab treatment for difficult-to-treat nephrotic syndrome in children: A multicenter study(Springer, 2018) Taşdemir, Mehmet; Canpolat, Nur; Yıldız, Nurdan; Özçelik, Gül; Benzer, Meryem; Saygılı, Seha Kamil; Özkayın, Neşe; Türkkan, Özde Nisa; Balat, Ayşe; Candan, Cengiz; Çelakıl, Mehtap Ezel; Yavuz, Sevgi; Akıncı, Nurver; Göknar, Nilüfer; Akgün, Cihangir; Tülpar, Sebahat; Alpay, Harika; Sever, Lale; Bilge, Ilmay[Abstract Not Available]Öğe Rituximab treatment for difficult-to-treat nephrotic syndrome in children: A multicenter, retrospective study(TÜBİTAK Scientific and Technological Research Council of Turkey, 2021) Taşdemir, Mehmet; Canpolat, Nur; Yıldız, Nurdan; Özçelik, Gül; Benzer, Meryem; Saygılı, Seha Kamil; Özkayın, Emine Neşe; Türkkan, Özde Nisa; Balat, Ayşe; Candan, Cengiz; Çelakıl, Mehtap; Yavuz, Sevgi; Akıncı, Nurver; Göknar, Nilüfer; Akgün, Cihangir; Tülpar, Sebahat; Alpay, Harika; Sever, Fatma Lale; Bilge, İlmayBackground/aim: This study aimed to evaluate the efficacy of rituximab in children with difficult-to-treat nephrotic syndrome, considering the type of disease (steroid-sensitive or -resistant) and the dosing regimen. Materials and methods: This multicenter retrospective study enrolled children with difficult-to-treat nephrotic syndrome on rituximab treatment from 13 centers. The patients were classified based on low (single dose of 375 mg/m(2)) or high (2-4 doses of 375 mg/m(2)) initial dose of rituximab and the steroid response. Clinical outcomes were compared. Results: Data from 42 children [20 steroid-sensitive (frequent relapsing / steroid-dependent) and 22 steroid-resistant nephrotic syndrome, aged 1.9-17.3 years] were analyzed. Eleven patients with steroid-sensitive nephrotic syndrome (55%) had a relapse following initial rituximab therapy, with the mean time to first relapse of 8.4 +/- 5.2 months. Complete remission was achieved in 41% and 36% of steroid-resistant patients, with the median remission time of 3.65 months. At Year 2, eight patients in steroid-sensitive group (40%) and four in steroid-resistant group (18%) were drug-free. Total cumulative doses of rituximab were higher in steroid-resistant group (p = 001). Relapse rates and time to first relapse in steroid-sensitive group or remission rates in steroid-resistant group did not differ between the low and high initial dose groups. Conclusion: The current study reveals that rituximab therapy may provide a lower relapse rate and prolonged relapse-free survival in the steroid-sensitive group, increased remission rates in the steroid-resistant group, and a significant number of drug-free patients in both groups. The optimal regimen for initial treatment and maintenance needs to be determined.
